These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 8496812)

  • 1. Cardioprotection in ischemic rat hearts with the SH-containing angiotensin-converting enzyme inhibitor zofenopril: possible involvement of the ATP-sensitive potassium channel.
    Sargent CA; Sleph PG; Dzwonczyk S; Smith MA; Normandin D; Antonaccio MJ; Grover GJ
    J Pharmacol Exp Ther; 1993 May; 265(2):609-18. PubMed ID: 8496812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [ACE inhibitors with SH groups have no effect of ATP-dependent K channels--a dissertation].
    Köppel H; Gasser R; Klein W; Holzmann S
    Acta Med Austriaca; 1996; 23(3):109-12. PubMed ID: 8967287
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protection of the ischemic myocardium by the converting-enzyme inhibitor zofenopril: insight into its mechanism of action.
    Ferrari R; Cargnoni A; Curello S; Ceconi C; Boraso A; Visioli O
    J Cardiovasc Pharmacol; 1992; 20(5):694-704. PubMed ID: 1280730
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cardioprotective effects of a novel calcium antagonist related to the structure of cromakalim.
    Grover GJ; Sleph PG; Dzwonczyk S; McCullough JR
    J Pharmacol Exp Ther; 1993 Oct; 267(1):102-7. PubMed ID: 8229736
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of potassium channel blockade on the anti-ischemic actions of mechanistically diverse agents.
    Sargent CA; Smith MA; Dzwonczyk S; Sleph PG; Grover GJ
    J Pharmacol Exp Ther; 1991 Oct; 259(1):97-103. PubMed ID: 1920138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glyburide-reversible cardioprotective effect of BMS-180448 is independent of action potential shortening.
    Grover GJ; D'Alonzo AJ; Hess T; Sleph PG; Darbenzio RB
    Cardiovasc Res; 1995 Nov; 30(5):731-8. PubMed ID: 8595620
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of cromakalim and glibenclamide on myocardial high energy phosphates and intracellular pH during ischemia-reperfusion: 31P NMR studies.
    Docherty JC; Gunter HE; Kuzio B; Shoemaker L; Yang L; Deslauriers R
    J Mol Cell Cardiol; 1997 Jun; 29(6):1665-73. PubMed ID: 9220352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic characterization of BMS-191095, a mitochondrial K(ATP) opener with no peripheral vasodilator or cardiac action potential shortening activity.
    Grover GJ; D'Alonzo AJ; Garlid KD; Bajgar R; Lodge NJ; Sleph PG; Darbenzio RB; Hess TA; Smith MA; Paucek P; Atwal KS
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1184-92. PubMed ID: 11356945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes and ATP-sensitive potassium channel openers and blockers in isolated ischemic/reperfused hearts.
    Tosaki A; Engelman DT; Engelman RM; Das DK
    J Pharmacol Exp Ther; 1995 Dec; 275(3):1115-23. PubMed ID: 8531071
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of a pharmacologic interaction between ATP-sensitive potassium channels and adenosine A1 receptors in ischemic rat hearts.
    Grover GJ; Baird AJ; Sleph PG
    Cardiovasc Res; 1996 Apr; 31(4):511-7. PubMed ID: 8689642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.
    Grover GJ; Sleph PG; Dzwonczyk S; Wang P; Fung W; Tobias D; Cushman DW
    J Pharmacol Exp Ther; 1991 Jun; 257(3):919-29. PubMed ID: 1646329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KATP channel opening does not contribute significantly to the vasodilatory effect of SH-group-containing ACE inhibitors.
    Köppel H; Holzmann S; Klein W; Horn E; Horn S; Gasser R
    Heart Vessels; 1996; 11(4):192-6. PubMed ID: 9119808
    [TBL] [Abstract][Full Text] [Related]  

  • 13. KATP channel modulation in working rat hearts with coronary occlusion: effects of cromakalim, cicletanine, and glibenclamide.
    Ferdinandy P; Szilvássy Z; Droy-Lefaix MT; Tarrade T; Koltai M
    Cardiovasc Res; 1995 Nov; 30(5):781-7. PubMed ID: 8595627
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protective effects of ATP-sensitive potassium-channel openers in experimental myocardial ischemia.
    Grover GJ
    J Cardiovasc Pharmacol; 1994; 24 Suppl 4():S18-27. PubMed ID: 7898104
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACE inhibition and protection from doxorubicin-induced cardiotoxicity in the rat.
    Sacco G; Mario B; Lopez G; Evangelista S; Manzini S; Maggi CA
    Vascul Pharmacol; 2009; 50(5-6):166-70. PubMed ID: 19344651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The cardioprotective, vasorelaxant and electrophysiological profile of the large conductance calcium-activated potassium channel opener NS-004.
    Sargent CA; Grover GJ; Antonaccio MJ; McCullough JR
    J Pharmacol Exp Ther; 1993 Sep; 266(3):1422-9. PubMed ID: 8371147
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cardioprotective and electrophysiological effects of cromakalim are attenuated by meclofenamate through a cyclooxygenase-independent mechanism.
    Grover GJ; D'Alonzo AJ; Sleph PG; Dzwonczyk S; Hess TA; Darbenzio RB
    J Pharmacol Exp Ther; 1994 May; 269(2):536-40. PubMed ID: 8182522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective effects against hydrogen peroxide-induced toxicity by activators of the ATP-sensitive potassium channel in isolated rat hearts.
    Gan XT; Cook MA; Moffat MP; Karmazyn M
    J Mol Cell Cardiol; 1998 Jan; 30(1):33-41. PubMed ID: 9500862
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardioprotective profile of the cardiac-selective ATP-sensitive potassium channel opener BMS-180448.
    Grover GJ; McCullough JR; D'Alonzo AJ; Sargent CA; Atwal KS
    J Cardiovasc Pharmacol; 1995 Jan; 25(1):40-50. PubMed ID: 7723352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does captopril attenuate reperfusion-induced myocardial dysfunction by scavenging free radicals?
    Westlin W; Mullane K
    Circulation; 1988 Jun; 77(6 Pt 2):I30-9. PubMed ID: 2836109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.